Divamics

Executive Summary

Divamics (Suzhou, China) is a preclinical-stage biotech company leveraging its proprietary BioTrajectory AI platform to accelerate drug discovery in autoimmune, metabolic, and inflammatory diseases. The platform integrates multi-scale molecular dynamics simulations with AI algorithms to achieve molecular precision in drug design, enabling the development of first-in-class and me-better therapeutics. Founded in 2020, the company has maintained a lean team of 10-50 employees and operates in the competitive Chinese biotech landscape. While still in early stages with no disclosed funding or pipeline, Divamics' AI-driven approach aligns with industry trends toward computational drug discovery, potentially reducing development timelines and costs. The platform's validation will be critical to attracting partnerships and investors.

Upcoming Catalysts (preview)

• Q3 2026Nomination of a lead candidate for an autoimmune indication using BioTrajectory AI40% success
• Q3 2026Series A funding round from Asian or global life science VCs30% success
• Q4 2026Research collaboration or licensing deal with a larger pharma company25% success